MarketCap
Facebook
X
TelegramQuarterly report 2024-Q2
added 07-25-2024
Morphic Holding Total Shareholders Equity 2011-2026 | MORF
Annual Total Shareholders Equity Morphic Holding
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 697 M | 349 M | 337 M | 145 M | 141 M | -52.6 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 697 M | -52.6 M | 269 M |
Quarterly Total Shareholders Equity Morphic Holding
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 618 M | 664 M | 697 M | 723 M | 729 M | 427 M | 349 M | 365 M | 388 M | 313 M | 337 M | 350 M | 348 M | 369 M | 145 M | 145 M | 145 M | 145 M | 141 M | 141 M | 141 M | 141 M | -52.6 M | -52.6 M | -52.6 M | -34.7 M | -29.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 729 M | -52.6 M | 281 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
967 M | $ 3.55 | -0.42 % | $ 1.06 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | Canada |
 |
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | USA |
 |
AC Immune SA
ACIU
|
215 M | $ 3.25 | 3.83 % | $ 229 M |  Schweiz |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
AgeX Therapeutics
AGE
|
5.47 M | - | -10.17 % | $ 12.2 K | USA |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M |  France |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
54.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aptorum Group Limited
APM
|
21.1 M | $ 0.79 | 0.03 % | $ 4.31 M | China |
 |
ADC Therapeutics SA
ADCT
|
166 M | $ 4.12 | -1.9 % | $ 105 M | Schweiz |
 |
Arcturus Therapeutics Holdings
ARCT
|
214 M | $ 6.55 | -1.28 % | $ 179 M |  Israel |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
35.5 M | $ 3.43 | -4.99 % | $ 8.25 B |  Australia |
 |
Ascendis Pharma A/S
ASND
|
884 M | $ 229.99 | -0.45 % | $ 5 B |  Danmark |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
275 M | $ 6.09 | 0.58 % | $ 496 M | USA |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Athersys
ATHX
|
16.4 M | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
AlloVir
ALVR
|
113 M | - | 4.14 % | $ 49.1 M | USA |
 |
BioCardia
BCDA
|
-1.6 M | $ 1.29 | 1.24 % | $ 27.3 M | USA |
 |
Anika Therapeutics
ANIK
|
212 M | $ 14.55 | 1.32 % | $ 213 M | USA |
 |
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aptose Biosciences
APTO
|
-4.54 M | - | -45.71 % | $ 1.2 M | Canada |
 |
AVEO Pharmaceuticals
AVEO
|
45.9 M | - | - | $ 521 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
19 M | $ 2.62 | -0.75 % | $ 16.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.8 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
427 M | $ 1.51 | - | $ 385 M | Britain |
 |
Athira Pharma
ATHA
|
44.8 M | - | - | $ 269 M | USA |
 |
BioNTech SE
BNTX
|
1.37 B | $ 94.12 | 3.95 % | $ 27.2 B | Germany |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Burford Capital Limited
BUR
|
1.7 B | $ 8.27 | 2.54 % | $ 1.34 B | Britain |
 |
AstraZeneca PLC
AZN
|
15.6 B | - | - | $ 96.9 B | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.44 M | $ 3.5 | -2.51 % | $ 7.62 B | Israel |